LDH-A CRISPR/Cas9 KO Plasmid (r): sc-437361
- Target species: rat
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LDH-A CRISPR/Cas9 Knockout (KO) Plasmid (r) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LDH-A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LDH-A Antibody (F-3): sc-137244
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LDH-A CRISPR/Cas9 KO Plasmid (r) | sc-437361 | 20 µg | $397.00 |
Overview
Lactate dehydrogenase A (LDH-A) catalyzes the interconversion of pyruvate and lactate with concomitant NADH/NAD⁺ cycling, a key reaction supporting anaerobic glycolysis and redox homeostasis. In rat cells, LDH-A helps sustain glycolytic flux under hypoxia and high energetic demand, influencing lactate production, cytosolic pH balance, and metabolic crosstalk with the TCA cycle. LDH-A activity is tightly linked to metabolic reprogramming programs that accompany proliferation and stress adaptation, including HIF-1–regulated responses and altered NAD⁺ availability. Dysregulated LDH-A–dependent lactate metabolism has been associated with pathological contexts such as ischemic injury, inflammation, and tumor-like metabolic phenotypes, making it a useful target for mechanistic studies of metabolic signaling.
LDH-A CRISPR/Cas9 KO Plasmid (r) is a pool of plasmids designed for targeted disruption of the gene in rat cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LDH-A protein expression.
This CRISPR knockout system enables efficient generation of -deficient cell models for investigation of LDH-A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting exon(s) critical for LDH-A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LDH-A CRISPR/Cas9 KO Plasmid (r) and LDH-A CRISPR/Cas9 KO Plasmid (r2) target distinct sites within the locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LDH-A HDR Plasmid (r) and LDH-A HDR Plasmid (r2) contain a puromycin resistance cassette and an RFP reporter flanked by homology arms to support homology-directed repair at defined target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.